Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Portal vein chemotherapy for colorectalcancer: a meta-analysis of 4000 patients in 10 studies Portal vein chemotherapy for colorectalcancer: a meta-analysis of 4000 patients in 10 studies Portal vein chemotherapy for colorectalcancer: a meta-analysis of 4000 patients in 10 studies Liver Infusion Meta-analysis Group Authors' objectives To assess the effects on tumour recurrence and survival of administering fluorouracil (5-FU)-based chemotherapy by portal vein infusion (PVI) after colorectal (...) by PVI for patients with colorectalcancer. Research: The authors stated that further large trials of post-operative treatment with 5-FU by PVI in patients with colorectalcancer are needed. Funding Imperial Cancer Research Fund; the Ligue Nationale Francaise Contre le Cancer; the Conseil General du Val de Marne; BIOMED Programme of the European Community, grant number PL 931247. Bibliographic details Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectalcancer: a meta-analysis
are not reported and the reader would have to obtain the individual reports to ascertain facts such as patient age range and gender. Without details of study design or patient characteristics, it is not clear to which patients with rectal carcinoma the results of the meta-analysis would be applicable. Bibliographic details Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectalcarcinoma: results of a meta-analysis. Diseases of the Colon and Rectum 1997; 40(1): 35-41 PubMedID Other publications (...) of follow-up, were included. Specific interventions included in the review Adjuvant chemotherapy including 5-fluorouracil. Participants included in the review Patients with Dukes C coloncancer receiving adjuvant chemotherapy and patients with Dukes B or C rectal carcinoma receiving radiotherapy and chemotherapy, were included. Trials involving liver perfusion were excluded. Outcomes assessed in the review The outcome was 5-year survival. How were decisions on the relevance of primary studies made
details Gyrd-Hansen D. Is it cost effective to introduce screening programmes for colorectalcancer? Illustrating the principles of optimal resource allocation. 1997; 41: 189-199 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; ColonicNeoplasms /prevention & Cost-Benefit Analysis; Denmark; Female; Health Care Rationing /economics; Health Policy; Humans; Male; Mass Screening /economics; Middle Aged; Rectal Neoplasms /prevention & Uterine Cervical Neoplasms /prevention (...) were the survival rate amongstpatients whose cancers were detected, the rate of adenomas detected due to screening which would have otherwise gone undetected, and the percentage of large adenomas (greater or equal to 1 cm in diameter). Effectiveness results It was reported that the mortality rate for colorectalcancer, over a period of 10 years "was significantly reduced in the screening group (mortality ratio 0.82 (0.68-0.99))". The survival rate amongst the patients whose cancers were detected
of various screening scenarios to the public, the development of optimal endoscopy procedures tailored to the specific demands ofscreening interventions and expected savings on the treatment of colorectalcancer. Source of funding Supported by the Dutch 'Praeventienfonds' and by the Dutch DigestiveDisease Foundation. Bibliographic details Geul K W, Bosman F T, van Blankenstein M, Grobbee D E, Wilson J H. Prevention of colorectalcancer: costs and effectiveness of sigmoidoscopy. Scandinavian Journal (...) of adenomas per colon. There were 100 autopsies in each of three age groups (50-59, 60-69 and 70-79). Study design The study was a cohort study. Analysis of effectiveness The primary outcome used in the analysis was the number of adenomas eliminated by an endoscopy programme. Effectiveness results An initial full colonoscopy could potentially detect 45 adenomas per 100 of the population, corresponding with a reduction of 60% in the total colorectalcancer risk in the population. Adequate follow-up
Cost analysis in a population based screening programme for colorectalcancer: comparison of immunochemical and guaiac faecal occult blood testing Cost analysis in a population based screening programme for colorectalcancer: comparison of immunochemical and guaiac faecal occult blood testing Cost analysis in a population based screening programme for colorectalcancer: comparison of immunochemical and guaiac faecal occult blood testing Castiglione G, Zappa M, Grazzini G, Sani C, Mazzotta (...) A, Mantellini P, Ciatto S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two faecal occult blood tests (FOBT) for colorectalcancer screening: Hemoccult (guaiac based) and reversed passive hemagglutination (RPHA) tests. RPHA tests were
) Dukes' B or C who were under 75 years old, had no concomitant malignancy, ulcerative colitis, Crohn's disease, renal, heart or liver failure and who were capable of undergoing one year of adjuvant therapy, were invited to participate. 95 patients were recruited, one patient proved to have Dukes' A and was excluded, so 94 (53 females, 41 males) were included. Their median age at diagnosis was 62 years (range: 36-76 years), 72% had coloniccarcinoma and 64% had Dukes' B and 34% Dukes' C CRC. 47 were (...) randomised to surgery plus ACT and 47 to surgery alone. Setting Patients were recruited from the three counties of northern Norway: Finmark (23), Troms (32) and Nordland (39). Patients were treated at the University Hospital of Tromso (UHT) and 8 other local hospitals. Dates to which data relate Patients were recruited from January 1993 to February 1996. Patient records were analysed in April 1996 with respect to sex, age at diagnosis, tumour location (rectal or coloniccarcinoma), Dukes' stage (B or C
A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectalcarcinoma: a cost-effectiveness analysis. Annals of Oncology 1997;8:65-70. Pihl E, Hughes ES, McDermot FT, et al. Disease free survival and recurrence after resection of colorectalcancer. Journal of Surgical Oncology 1981;16:333-41. Indexing Status Subject indexing assigned by NLM MeSH Carcinoembryonic Antigen /analysis /economics; ColonicNeoplasms /economics /mortality /therapy; Colonoscopy; Cost-Benefit Analysis (...) limitations. The authors recommend considering the exclusion of CEA monitoring as an indicator for second-look surgery, which can improve the cost-effectiveness of the follow-up programme. Source of funding None stated. Bibliographic details Norum J, Olsen J A. A cost-effectiveness approach to the Norwegian follow-up programme in colorectalcancer. Annals of Oncology 1997; 8: 1081-1087 PubMedID Other publications of related interest Berge I, Ekelund C, Mellner BP. Carcinoma of the colon and rectum
Two phase III trials of tauromustine (TCNU) in advanced colorectalcancer. 8624301 1996 06 26 2016 10 17 0923-7534 6 9 1995 Nov Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Two phase III trials of tauromustine (TCNU) in advanced colorectalcancer. 948-9 Smyth J F JF Department of Clinical Oncology, Western General Hospital, Edinburgh, UK. Hardcastle J D JD Denton G G Alderson D D Grace R H RH Mansi J L JL Yosef H M HM Nordle O O Lauri H H Wählby (...) S S eng Clinical Trial Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial England Ann Oncol 9007735 0923-7534 0 Antineoplastic Agents 0 Nitrosourea Compounds 1EQV5MLY3D Taurine 511F69K76Y 1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea U3P01618RT Fluorouracil IM Ann Oncol. 1996 Feb;7(2):211 8777181 Aged Antineoplastic Agents administration & dosage therapeutic use ColorectalNeoplasms drug therapy pathology Female
Randomised study of screening for colorectalcancer with faecal-occult-blood test. Case-control studies and a voluntary-based follow-up study have suggested that repeated screening with faecal-occult-blood (FOB) tests can lead to a reduction in mortality from colorectalcancer (CRC). The aim of this randomised study was to compare mortality rates after FOB tests every 2 years during a 10-year period with those of unscreened similar controls.140,000 people aged 45-75 years lived in Funen
Randomised controlled trial of faecal-occult-blood screening for colorectalcancer. There is growing evidence that faecal-occult-blood (FOB) screening may reduce colorectalcancer (CRC) mortality, but this reduction in CRC mortality has not been shown in an unselected population-based randomised controlled trial. The aim of this study was to assess the effect of FOB screening on CRC mortality in such a setting.Between February, 1981, and January, 1991, 152,850 people aged 45-74 years who lived (...) with those who tested positive but in whom no neoplasia was found on colonoscopy, were invited to take part in further screening every 2 years. Screening was stopped in February, 1995, by which time screening-group participants had been offered FOB tests between three and six times. Screening-group participants who had a positive test were offered full colonoscopy. All participants were followed up until June, 1995. The primary outcome measure was CRC mortality.Of the 152,850 individuals recruited
1996LancetControlled trial quality: predicted high
, Segala M, Capko D, Andreoni B, Tiberio G. Follow-up in colorectalcancer patients: a cost-benefit analysis. Annals of Surgical Oncology 1996; 3(4): 349-357 PubMedID Indexing Status Subject indexing assigned by NLM MeSH ColonicNeoplasms /economics /mortality /surgery; Cost-Benefit Analysis; Humans; Monitoring, Physiologic /economics; Neoplasm Recurrence, Local; Postoperative Care /economics; Rectal Neoplasms /economics /mortality /surgery; Survival Rate AccessionNumber 21996000743 Date bibliographic (...) assessment on the reliability of the study and the conclusions drawn. Health technology Clinical follow-up after curative surgery for colorectalcancer. Type of intervention Treatment and palliative care. Economic study type Cost-effectiveness analysis. Study population Patients who survived curative surgery for stage I-III colorectaladenocarcinoma. The mean age was 65.2 years. Patients with stage IV colorectaladenocarcinoma were excluded from the study. Setting Hospital. The economic study was carried
5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectalcancer 5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectalcancer 5-fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectalcancer Bliss E, Robert G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bliss E, Robert G. 5 (...) -fluorouracil (5-FU) as adjuvant chemotherapy in Duke's stage C colorectalcancer. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1996 Authors' objectives The authors examine how worthwhile is the proposal that all patients with Duke's stage C colorectalcancer be offered 5-fluorouracil (5-FU) as adjuvant chemotherapy following surgery. Authors' conclusions There are undoubted benefits, but in view of side effects the cost of QALYs is likely to be at the upper end of the range
emission tomography. Descriptive analysis of experience with PET in VA. A systematic review update of FDG-PET as a diagnostic test in cancer and Alzheimer's disease. Technology Assessment Program. Boston (MA): Veterans Affairs Medical Center, Health Services Research and Development Service; 1998. Report No.: 10. Indexing Status Subject indexing assigned by CRD MeSH ColorectalNeoplasms; Diagnostic Techniques and Procedures; Tomography, Emission-Computed AccessionNumber 11997008387 Date bibliographic (...) provide a range of data on the demographic and clinical characteristics of patients on whom PET studies are performed, and on their clinical outcomes in a variety of settings. The use of PET to avoid unnecessary surgery by detecting unresectable recurrent disease in patients who are scheduled for surgery based on other imaging and blood chemistry studies should be systematically addressed in larger patient samples. If it is demonstrated that post-operative follow-up in colorectalcancer patients
on the reliability of the study and the conclusions drawn. Health technology Oral ftorafur, an in-vivo pro-drug (tetrahydro-2-furanyl derivative of 5-fluorouracil) and a known antineoplastic agent in colorectalcancer. Type of intervention Treatment. Economic study type Cost-effectiveness and cost-utility analyses. Study population The study population comprised elderly patients who had undergone resection of histologically confirmed adenocarcinoma of the largebowel and rectum, who had not yet given (...) ftorafur and leucovorin is at least as effective as, and much less costly than, the current standard IV therapy (5-FU and leucovorin) in terms of providing significant anti-tumour effect, palliation, ease of administration and relatively few side effects. A home treatment programme based on oral ftorafur may be the most desirable option for all patients with advanced colorectalcarcinoma. CRD COMMENTARY - Selection of comparators The reason for the choice of comparators is clear. Validity of estimate
Calcium does not protect against colorectalneoplasia Calcium does not protect against colorectalneoplasia Calcium does not protect against colorectalneoplasia Bergsma-Kadijk J A, van't Veer P, Kampman E, Burema J Authors' objectives To assess whether calcium decreases the risk of colorectalneoplasia by binding bowel-irritating compounds and diminishing mucosal proliferation. Searching MEDLINE was searched from January 1980 to September 1994 with the following keywords: 'site' ('colon (...) ', 'rectum', 'colorectal'), 'endpoint' ('cancer', 'carcinoma', 'tumour', 'polyps', 'hyperproliferation') and 'calcium' ('calcium diet', 'dietary', 'dairy'). Current Contents for 1994 (July to September) and the reference lists of retrieved papers were also examined. Study selection Study designs of evaluations included in the review Cohort and case-control studies were included. Specific interventions included in the review Calcium intake. Participants included in the review Men and women were included
regional chemotherapy to the liver should be offered to patients with isolated liver metastases after curative resection of colorectalcancer may depend on the cost-effectiveness of the procedure. On present evidence, it appears to improve survival in the short-to-medium term. Bibliographic details Harmantas A, Rotstein L E, Langer B. Regional versus systemic chemotherapy in the treatment of colorectalcarcinoma metastatic to the liver: is there a survival difference? Meta-analysis of the published (...) literature. Cancer 1996; 78(8): 1639-1645 PubMedID Other publications of related interest DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. Indexing Status Subject indexing assigned by NLM MeSH ColorectalNeoplasms /mortality /pathology; Floxuridine /administration & Fluorouracil /administration & Humans; Infusions, Intra-Arterial; Liver Neoplasms /drug therapy /mortality /secondary; Survival Rate; Treatment Outcome; dosage; dosage AccessionNumber 11996001716
Cholecystectomy as a risk factor for colorectalcancer: a meta-analysis Cholecystectomy as a risk factor for colorectalcancer: a meta-analysis Cholecystectomy as a risk factor for colorectalcancer: a meta-analysis Reid F D, Mercer P M, Harrison M, Bates T Authors' objectives To evaluate whether cholecystectomy is associated with an increased risk of colorectalcancer. Searching A computerised search of MEDLINE was performed in addition to manual searches. Study selection Study designs (...) of evaluations included in the review Case-control studies and cohort studies were included. Specific interventions included in the review Cholecystectomy. Participants included in the review Patients with colorectalcancer and age-sex-matched controls without colorectalcancer were included. Outcomes assessed in the review The number of patients with colorectalcancer was assessed. How were decisions on the relevance of primary studies made? The authors do not state how the papers were selected
of colorectalcancer was 23 per 1,000 (95% CI: 21 - 26) for the annual screen group and 26per 1,000 (CI: 23 - 28) for the control group; the cumulative mortality results were 5.88 (CI: 4.61 - 7.15) and 8.83 (CI: 7.26 - 10.4) for the annual-screen and control groups respectively. There were four cases of perforation of the colon per 12,246 colonoscopies carried out and 11 incidents of serious bleeding. Clinical conclusions The Minnesota trial showed a 33% reduction in colorectalcancer mortality (...) Cost-effectiveness analysis of screening by faecal occult blood testing for colorectalcancer in Australia Cost-effectiveness analysis of screening by faecal occult blood testing for colorectalcancer in Australia Cost-effectiveness analysis of screening by faecal occult blood testing for colorectalcancer in Australia Salkeld G, Young G, Irwig L, Haas M, Glasziou P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each
, sigmoidoscopy and colonoscopy. The surgical technologies for treating the disease were colectomy and hepatic resection. Type of intervention Diagnosis and treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised 12,150 patients with a diagnosis of carcinoma of the colon and rectum, of whom 6,607 were listed with hepatic metastases. Setting The large, nationwide hospital system operated by the US Department of Veterans Affairs (DVA) was the setting (...) . Outcomes after detection of metastatic carcinoma of the colon and rectum in a national hospital system. Journal of the American College of Surgeons 1996; 182(4): 353-361 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Carcinoma /economics /secondary /surgery; Colectomy; ColorectalNeoplasms /economics /pathology /surgery; Hospitals, Veterans; Humans; Liver Neoplasms /secondary; Lung Neoplasms /secondary; Medical Records; Retrospective Studies; Survival Analysis; Treatment Outcome
Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectalcancer Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectalcancer Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectalcancer Messori A, Bonistalli L, Costantini M, Trallori G, Tendi E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Adjuvant intraportal chemotherapy in patients with colorectalcancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population 252 colorectalcancer patients received adjuvant intraportal chemotherapy and 253 controls with colorectalcancer received no adjuvant chemotherapy. No other information about